Copenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (CoMPACT) trial: study protocol for a randomized, double-blinded, sham-controlled, three-armed, parallel-group trial of transcranial magnetic stimulation for treatment-resistant depression
Oct 2026· Frontiers in Psychiatry· Vol 17· 0 citations· 81 references
Medicine
TL;DR
By testing a novel stimulation protocol and evaluating the efficacy of a new parietal target, this study will help advance the development of innovative, circuit-based interventions for TRD, with potential implications for broader applications across neuropsychiatry.
Abstract
Background Treatment-resistant depression (TRD), characterized by poor response to conventional antidepressant therapies, remains a major clinical challenge. Repetitive transcranial magnetic stimulation (TMS) of the left dorsolateral prefrontal cortex (dlPFC) has emerged as a promising alternative. Employing intermittent theta burst stimulation (iTBS), TMS protocols have yielded rapid antidepressant effects in recent accelerated treatment studies. These findings warrant further investigation in larger samples to confirm efficacy and in-depth investigation into the underlying mechanisms. Moreover, other cortical sites may also represent suitable targets for accelerated iTBS treatment of TRD. Methods This randomized, double-blind, sham-controlled trial will assess the efficacy, feasibility and mechanisms of a novel, personalized, and accelerated iTBS protocol for TRD, targeting two left hemispheric regions, the left dlPFC and inferior parietal lobule (IPL), both characterized by anticorrelated functional connectivity with the subgenual anterior cingulate cortex. 78 adults (aged 18–95 years) will be recruited from Danish mental health centers and randomly assigned to one of three groups: (1) active iTBS of the left dlPFC, (2) active iTBS targeting of the left IPL, or (3) sham iTBS at either site. The intervention includes five daily sessions over five consecutive days. Targeting informed by group-level functional connectivity will be combined with individualized coil placement and stimulation dosing using electric field modeling based on whole-brain anatomical magnetic resonance imaging (MRI). Antidepressant efficacy will be evaluated using the 6-item Hamilton Depression Rating Scale as the primary outcome, assessed at an early post-intervention follow-up (F1) within three days after the final stimulation session. Multimodal post-treatment assessments, including MRI, will be conducted within five days after the intervention (T1). A four-week follow-up (T2) will assess the durability of clinical and cognitive outcomes. Neurophysiological mechanisms will be investigated using electroencephalography as well as structural and functional MRI. Discussion By testing a novel stimulation protocol and evaluating the efficacy of a new parietal target, this study will help advance the development of innovative, circuit-based interventions for TRD, with potential implications for broader applications across neuropsychiatry. Clinical trial registration https://clinicaltrials.gov/, identifier NCT06895863.
Accelerated intermittent theta burst stimulation (aiTBS) is an effective neuromodulatory intervention for treatment resistant depression (TRD). aiTBS delivers repetitive transcranial magnetic stimulation sessions over a compressed timeframe and can be individualized to specific locations using resting-state functional...
L. Appelbaum, Louise A. Stolz, Yin-Ming Sun et al.· Journal of Affective Disorde...· 0 citations
Daily high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex (DLPFC) is an established treatment for depression that has not responded to medication, but a standard course takes four to six weeks of sessions that can last close to 40 minutes each. Intermittent thet...
Ayushi Saxena· International Journal For Mu...· 0 citations
The cerebellum plays a crucial role in cognitive processing and thus presents a promising therapeutic target for Alzheimer’s disease (AD). This trial aims to evaluate the efficacy and safety of long-term, neuronavigated cerebellar intermittent theta burst stimulation (iTBS) in patients with AD. The ACT-AD trial is a mu...
Xin Zhang, Wen Li, Zhong-Qing Sun et al.· Trials· 0 citations
Major depressive disorder (MDD) has previously been associated with accelerated brain ageing, a feature reported to remain unchanged after antidepressant pharmacotherapy. We conducted a secondary analysis of a randomized trial augmenting cognitive behavioral therapy (CBT), a long-established first-line treatment for de...
M. Faria, Steve Pilling, Jonathan P. Roiser et al.· Journal of Psychiatric Resea...· 0 citations
BACKGROUND
Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but these benefits diminish within days. Whether intermittent theta-burst stimulation (iTBS) can sustain ketamine response and whether such effects are associated with changes in large-scale brain networks are unclear....
Tung-Ping Su, Mao-Hsuan Huang, Wan-Chen Chang et al.· Psychiatry and Clinical Neur...· 0 citations
High-frequency rTMS targeting the left DLPFC was associated with a statistically significant reduction in monthly moderate-to-severe headache days compared with sham in adults with pPTH 4-5 months post-trauma.
C. Nygaard, S. Kothari, H. Schytz et al.· Headache· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.